Mentari Therapeutics
1 known investors
Mentari Therapeutics develops targeted biological therapies for migraine treatment, focusing on PACAP pathway inhibition through monoclonal and bispecific antibodies for patients with inadequate relief from existing anti-CGRP therapies.
BiotechDigital Health
Investors · 1
In the news
- InMed and Mentari Therapeutics Merge to Advance Migraine Pipeline Backed by $290 Million Financing | citybizcitybiz.co · 2026
- Mentari Therapeutics to go public via InMed (NASDAQ: INM) mergerstocktitan.net · 2026
- A migraine drugmaker heads to the public markets through reverse merger | BioPharma Divebiopharmadive.com · 2026
- Migraine prevention push: InMed, Mentari merge with $290M fundingstocktitan.net · 2026
- Mentari takes its Paragon-discovered pipeline of migraine drugs public | FirstWord Pharmafirstwordpharma.com · 2026